This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on https://www.researchprotocols.org, as well as this copyright and license information must be included.
Dental fear and anxiety (DFA) is a condition that affects approximately one-quarter of children and adolescents. It is a significant cause for pediatric patients to avoid dental care later in adulthood. Lack of patient cooperation due to DFA can create an environment of stress, often obligating dentists to end appointments prematurely and consider alternative pharmacological treatment options. Virtual reality (VR) use during dental care, providing an immersive experience through sensory stimuli, is potentially an additional nonpharmacologic tool to better manage DFA in children with special health care needs (SHCN) undergoing dental procedures.
This pilot study aims to assess the feasibility and acceptability of VR immersion as a tool to reduce DFA in pediatric special needs patients undergoing dental procedures. The study also aims to gain insight on parent and health care provider perspectives on the use of VR during dental appointments.
This pilot randomized controlled trial study will follow a parallel design including 2 groups: a control group (clinic’s standard care using a wall TV) and an experimental group (using a VR game). We will randomize 20 participants to either group. Recruitment will be carried out at the dental clinic of the Centre Hospitalier Universitaire Sainte-Justine, a tertiary-quaternary care center that mostly serves pediatric patients with SHCN. The primary outcome will be patient recruitment rates and completion rates of planned procedures. DFA in children will be assessed using both an observation-based proxy assessment with the Venham Anxiety and Behavior Rating Scale and physiological assessments using parameters such as change in heart rate and levels of salivary alpha-amylase as a stress biomarker before and 10 minutes after the procedure. Sociodemographic characteristics, measures of the levels of parent and health care professional satisfaction, occurrence of side effects, and any deviation from normal procedure length will also be collected. Descriptive statistics, nonparametric tests, and effect sizes will be used for demographic and clinical variables and to present parent and health care professional satisfaction levels as well as procedural time.
This study will be conducted from May 2023 to May 2024, with results expected to be available in December 2024.
The pilot study will provide insight on the feasibility and acceptability of VR use in clinical dentistry to reduce DFA for pediatric patients with SHCN. This study will guide future research on VR use in pediatric dentistry and can serve as a framework for a larger randomized clinical trial.
ClinicalTrials.gov NCT05898100; https://classic.clinicaltrials.gov/ct2/show/NCT05898100
DERR1-10.2196/49956
Dental fear and anxiety (DFA) is a condition that affects approximately 13.3% to 29.3% of children and adolescents and is a significant cause of patients avoiding dental care [
Dental patients with special health care needs (SHCN) are defined as patients requiring additional time and special consideration when receiving treatment due to medical, physical, cognitive, or developmental conditions [
Understanding and assessing DFA in children are important for delivering successful dental care with high satisfaction in this age group. Among the vast number of assessment method options available today, self-report assessment, parental proxy assessment, observation-based assessment, and physiological assessment are the 4 major types for DFA in children [
Factors in the dental setting that trigger DFA include the loud sounds of dental instruments, presence of strangers examining the oral cavity, and the fear of pain [
Particularly when treating children with SHCN, extra time and tools are needed to provide comfortable dental care. Depending on the child’s diagnosis, some have hypersensitivity to external stimuli such as loud noises, aversion to specific tastes, and difficultly straying from usual daily routines [
VR is defined as an artificial environment that is experienced through sensory stimuli [
The aims of the study are twofold: (1) assess the feasibility and acceptability of VR immersion as a tool to reduce DFA in pediatric patients with SHCN undergoing dental procedures and (2) gain insight on parent and health care provider perspectives on the use of VR during dental appointments.
The primary research objectives are to determine (1) the feasibility and acceptability of VR distraction for children with special needs requiring dental procedures, (2) compare parent and health care professional satisfaction levels between the VR distraction group and the clinic’s standard mounted TV showing cartoons, and (3) observe the preliminary effects of VR distraction on reducing patient anxiety during dental procedures compared with standard nonpharmacological behavior management.
The secondary objectives of this study are to compare the following between the VR distraction group and the clinic’s standard mounted TV showing cartoons: (1) physiological parameters (pulse and oxygen saturation), (2) the occurrence of side effects, (3) dental procedure length, (4) the number of retakes of dental procedures due to DFA, and (5) salivary amylase levels.
This randomized controlled trial pilot study will follow a parallel design including 2 groups: a control group (mounted wall TV playing cartoons) and an experimental group (VR intervention during the dental procedure).
This pilot will include 20 participants, totalling 10% of the expected 200 children to be included in the final study. All participants in this pilot study will be allocated in an equal ratio of 10 per group. Recruitment will be carried out at the dental clinic of the Centre Hospitalier Universitaire Sainte-Justine, a pediatric hospital in Montreal, Canada. This clinic mostly serves patients with SHCN such as craniofacial abnormalities, autism spectrum disorder, cancer, and others. Pediatric patients with SHCN represent around 80% of the total clientele of this clinic, while the rest is comprised of otherwise healthy patients with dental traumas and other dental emergencies.
Children participating in this study will have to meet the following criteria: (1) aged 6 years to 17 years; (2) recommended by the dentist to participate; (3) required to undergo any dental procedure; and (4) accompanied by a parent or a legal guardian who can understand, read, and write in either French or English.
Participants will be excluded from this study if they meet the following criterion: have epilepsy or any other conditions preventing them from using VR. Non-SHCN patients will not be excluded from the study, but this information will be collected. Patients with a strong history of motion sickness will not be excluded from this study, but this information will be collected and additional monitoring will be provided. The use of medication (opioid and non-opioid analgesic, antiemetic, anxiolytic, or any other drugs) prior to the procedure within the last 4 hours will not exclude participants from this study, but this information will be collected during the pre-intervention questionnaire. Patients having undergone previous dental procedures in the past will not be excluded.
Randomization will be done through the electronic REDCap (Vanderbilt University) system. Allocation to either intervention will be randomized by an independent biostatistician from the Applied Clinical Research Unit (URCA). To equalize participants in both arms, permuted block randomization with a randomly selected block size design will be used to randomize participants to the intervention [
The control group will only receive a care-as-usual approach. This includes a television mounted on the wall showing cartoons and the use of pharmaceutical treatment during the procedure such as the use of injected local anesthesia. In the event of noncooperation during the appointment, any retakes or rescheduling of appointments will be compiled by the resident dentist. One parent will be permitted to be present in the room during the procedure as part of the clinic’s usual protocol, and their presence will be recorded. Children allocated to the control group will be offered the possibility to try the VR game after the study period if they choose to do so.
The experimental group will be provided the VR video game “Dental Dream” designed specifically for this study. Pharmaceutical treatment, such as the use of injected local anesthesia, during the procedure will be used if the procedure requires it. Children will be able to play for the entire duration of the dental procedure. “Dental Dream” aims to reduce anxiety in children aged 6 years to 17 years old by means of immersive distraction. The VR headset offers children the ability of viewing the game they are playing in real time while simultaneously obstructing the partial view they would normally have of the procedure. In the event of noncooperation during the appointment, any retakes or rescheduling of appointments will be compiled by the resident dentist. One parent will be allowed in the room during the dental procedure, and their presence will be recorded.
Developed by Paperplane Therapeutics, “Dental Dream” is an easy-to-play, immersive VR video game tailored for the pediatric population and approved by a team of health care professionals in pediatric care. The simplified no-success game allows it to be enjoyable no matter the child’s video game experience, and its point-and-shoot arcade style also allows for easy understanding and fast immersion in the game. Positioning is normally a challenge for VR as it is very position-specific, needing a semi-fowler's angle of 30°-45° to function properly. “Dental Dream” was designed specifically for this study with the specific horizontal position needed for dental procedures in mind. “Dental Dream” is designed to be supported by the Pico Neo 4 VR headset.
Children playing the game will be immersed through a virtual environment where they will be able to use a remote in one hand to target floating and static objects in the VR game. The objective of the game is to throw balls at targets such as balloons, trolls, and diamonds to gain points. The “Dental Dream” game uses an on-rail feature guiding the child through space with a new eye tracking technology developed within the headset in order to help the child navigate the same way head movement normally would in classic VR, making it easier for dental procedures where head movement is restricted. These features also aim to reduce cybersickness.
The preliminary version of the VR headset has been tested in clinic on staff—the size and volume of the Pico Neo 4 headset do not hinder delivery of dental care as it is smaller than usual VR headsets.
Sociodemographic data will be assessed before the intervention at baseline (T0) to establish a baseline using a simple questionnaire completed by the parent or legal guardian present while sitting in the waiting room. Salivary alpha-amylase samples will be collected at T0 and after the intervention/procedure (T2;
Sociodemographic characteristics will be provided by the parent or legal guardian in the waiting room prior to the intervention and will include information such as age, sex, ethnicity, and the procedure needed. Other information will also include any medication taken within the last 24 hours (name, class, and posology) that could have an impact on the conclusions of this study.
To measure feasibility and patient acceptability, we will record patient recruitment rates, completion rates of planned procedures, and satisfaction. As this is a population of children with SHCN, we estimate 50% of patients will agree to participate during recruitment, and we expect a completion rate of planned procedures of 75%.
Parent or legal guardian satisfaction with the intervention will be assessed using a visual analog scale (VAS; 0-10, where 0 is very dissatisfied and 10 is very satisfied) and the question recommended by the Pediatric Initiatives on Methods, Measurement and Pain Assessment in Clinical Trials (PedIMMPACT): “Considering anxiety relief, side effects and emotional recovery, how satisfied were you with the intervention used to manage DFA experienced by your child?” [
Health care professional satisfaction with the intervention will be assessed using a VAS (ranked from 0-10, where 0 is very dissatisfied and 10 is very satisfied) as well as a 6-question satisfaction questionnaire (each answer will be given a score of 1, 2, 3, or 4 based on the choice of answer: Fortement en désaccord, En désaccord, En accord, Fortement en accord, respectively) and will result in a final score between 6 and 24 (
DFA scores will be evaluated using the Venham Anxiety and Behavioral Rating Scale [
The secondary outcomes will be (1) changes in physiological parameters (such as heart rate and pulse oximetry) during and after the intervention compared with baseline, (2) occurrence of side effects, (3) deviation from the normal procedure length, (4) rescheduling of procedures in the event cooperation is impossible, and (5) salivary amylase levels.
The secondary outcomes will be measured as described here. Physiological parameters will be continuously measured using the Nellcor pulse oxygen saturation meter (Covidien), an approved and validated device. The occurrence of side effects will be collected from arrival on site to discharge from the study using a checklist of common side effects experienced while using VR and also related to dental medication. The length of the procedure will be measured and collected for every participant and will be compared with the average duration for a similar procedure that will have been measured prior to the study by the clinic’s personnel. Rescheduling of procedures in the event that cooperation is impossible will be noted. Salivary amylase levels, as a stress biomarker, will be measured before and after the dental procedure as described in the following section.
Saliva samples will be collected from all children in this study at 2 different study time periods: before (T0) and after (T2) the intervention. Salivary alpha-amylase has been recognized and validated as a reliable and specific marker for autonomic nervous system activity and has been proposed as an alternative biomarker for stress [
Salivary samples will be collected using a sterile dental cotton swab from under the tongue 10 minutes before and 10 minutes after the procedure and stored immediately within a sterile vile in a research-specific on-site freezer. Samples will be collected by the dental resident and taken to the laboratory. Results will be entered in REDCap for analysis after the study.
Questionnaires and corresponding respondents.
|
|
|
|
Participants will be identified by the resident dentist through the appointment scheduling system as requiring any dental procedure. Since DFA can arise from multiple different procedures such as simple cleaning to teeth extraction, dentists at the clinic will identify possible participants to include based on their cooperation, personality, and fears. An individual independent to the study will review consent with participants and parents. Written consent by the parents or legal guardian—including the child’s assent—will be obtained on arrival at the clinic the day of the procedure while completing the preprocedural questionnaire.
After verifying that the participant meets all the inclusion and exclusion criteria, the dental resident will log into REDCap only 10 minutes before the start of the intervention to minimize the risk of bias toward the intervention and to obtain the group allocation and announce it to the participant. Because of the nature of VR, no blinding of staff, participants, and parents or legal guardians will be possible. Baseline data collection prior to the dental procedure, including the sociodemographic questionnaire, recording of physiological parameters, and salivary alpha-amylase sampling, will take approximately 15 minutes to complete. The VR headset will be adjusted for the child’s size, and approximately 5 minutes will be allotted for children to familiarize themselves with the room, equipment, and game before the start of the procedure.
The intervention will last the entire time of the dental procedure, and the duration will be recorded for every patient. DFA assessment by proxy using the Venham Anxiety and Behavioral Rating Scale will be performed on site by the dental resident present and will also be filmed (if consent was given) to be evaluated by another member of the team at a later date.
As per the clinic’s protocol, if a child becomes restless and cooperation is impossible, the child will be held by his or her parents for the remaining duration of the procedure if it cannot be safely stopped at that time or if the procedure is considered an emergency. If the procedure can be safely stopped, rescheduling will be discussed with the parents including the possible need for sedation. The involvement of parents will be recorded as well as any other distractions used during treatment such as the use of stickers, teddy bears, or music.
All side effects and medication used will be recorded. The former will be transmitted to the ethics committee if needed. As VR has the potential to cause nausea, dizziness, and motion sickness, should participants experience any of these, they will be dealt with according to the clinic’s protocols. If participants experience adverse side effects and the attending dentist and dental assistant have been informed, the treatment will be safely discontinued. All instruments in the mouth will be removed. The VR device will be removed from the participant. The dental chair will be placed in a comfortable position, and the patient will rest until they feel comfortable and recovered. The option of continuing the treatment (without the VR headset) or postponing the treatment to another day will be discussed. Postprocedure salivary alpha-amylase sampling and completion of questionnaires regarding parent and health care professional satisfaction levels after the dental procedure will take approximately 20 minutes. Equipment used by children will be disinfected before the next participant arrives.
Analysis will be conducted using the SAS (SAS Institute) statistical analysis software (version 9.4). Descriptive statistics, by treatment, will be conducted for demographic and clinical variables and will be used to present sociodemographic and clinical data, parent and health care professional satisfaction levels, and procedural time. Due to a small sample size, we will also assess effect sizes.
For the pilot project, we plan to perform descriptive analyses of the sample as well as comparative analyses between the 2 groups. Nonparametric tests for procedural type, age, parental presence, parental and health care satisfaction levels, and baseline (T0) anxiety score measurement will be used to assess the composite outcome for mean salivary cortisol level and mean difference in anxiety score (using the Venham Clinical Cooperation Scale and Venham Clinical Anxiety Scale) between the experimental and control groups at T2. Analyses will be carried out according to the intention-to-treat principle, with a significance level (α) of .025, considering Bonferroni's correction.
For secondary outcome analyses, nonparametric tests adjusted for procedural type, age, and parental presence will be used to assess the mean procedural length at T2 using the VAS and 6-item tailored questionnaire, respectively. Comparison of dichotomous variables including the necessity for procedural retakes, use of other nonpharmacological interventions, and the occurrence of side effects will be assessed using the Cochran-Mantel-Haenszel test.
The study data will be recorded in the REDCap system belonging to URCA. The data manager associated with URCA and independent of the study will be responsible for the storage of the recorded data. However, a URCA biostatistician independent of the study will be responsible for the data analysis. The data analysis plan will be discussed with the principal investigator (SLM). Interjudge correlations will be conducted for the video tape analysis. Two judges will independently rate the anxiety measure on the videotapes. Subsequently, we will conduct intraclass correlation coefficient analyses to compare the scores for each of the recruited patients between the 2 judges.
Approval by the Ste-Justine Hospital research board of ethics (#2023-4985) was obtained in March 2023. An individual independent to the study will review consent with participants and parents. The information and consent form will be signed by one of the parents on the day of the visit. Upon enrollment, children are assigned codes used on all data collection forms to protect their confidentiality. Only the dental resident and the principal investigator will have access to the log that links the study codes to the participants. Patient-identifying information is kept separate from the case reports and is linked to study enrollment by a study ID number. The consent form also identifies all the information that may be collected during this study and details the use of videos that may be needed for further behavior evaluation using proxy scales with the possibility to opt out. All data collected by paper forms the day of the intervention will subsequently be transferred into REDCap. No recording of the child’s screen nor their game inputs will be collected. The intervention will be filmed and recorded, as the use of proxy scales will need further evaluation of the child’s behavior. As per usual, all information such as links between patient identifiers to study ID and paper copies of forms and questionnaires will be kept stored and double locked for 7 years (starting from the end of trial) at the principal investigator’s office at the research center.
This study will be conducted from May 2023 to May 2024, with results expected to be available in December 2024. The findings of the study will be disseminated through peer-reviewed publications.
The results of the study will allow us to gain insight on the feasibility and acceptability of the intervention and on the satisfaction of parents and health care professionals regarding the use of VR as a tool to reduce anxiety in pediatric dentistry, especially in children with SHCN. Due to the limited clinical studies about VR and pediatric SHCN populations in dentistry, this pilot study will guide potential future, larger, clinical trials.
Individual experience with VR varies immensely, as some children may love to have an active distraction during dental treatment, while others may prefer to be present in the moment. As such, we acknowledge that the acceptance of VR use during dental treatment is a tool that may be useful for a certain population within a patient pool. Like all other distraction tools used in the dental setting, proper screening and patient selection are crucial during treatment planning. Moreover, the game design used during the study was created specifically for our study, so the results of our study may not be able to be extrapolated to a different setting with a different game design.
The results of the study could be used to help us to better understand how VR distraction can reduce DFA in children with special needs and the acceptability of its use by parents, patients, and health care professionals during dental procedures. The results can be used as preliminary data for a future clinical trial on the use of VR in dentistry with special needs patients. In addition, this study will possibly allow for more comfortable and less traumatic dental care for pediatric patients. By exploring new avenues for behavior and anxiety management tools for pediatric dentistry, this study and its results will provide improved patient-centered care.
Once the pilot study is completed, the authors confirm that the data supporting the findings of this study will be available through the clinicaltrials.gov repository. In addition, data will be available within a future publication and its supplementary materials.
Study time points and data collection.
Parental satisfaction questionnaire.
Healthcare professional satisfaction questionnaire.
Venham anxiety and behavioral rating scale.
dental fear and anxiety
special health care needs
Applied Clinical Research Unit
visual analog scale
virtual reality
None declared.